MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?
Biomolecules · 23.05.2023 · 13 (6) · 877
DOI: 10.3390/biom13060877 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 23.05.2023. Verfasst von Han Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Special Key Laboratory of Gene Detection and Therapy of Guizhou Province, Zunyi Medical University, Zunyi 563000, China. Hauptthemen laut MEDLINE: MicroRNAs, Lung Neoplasms. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Project of the Guizhou Provincial Department of Science and Technology, Collaborative Innovation Center of the Chinese Ministry of Education.
Abstract (Originalsprache)
Lung cancer is a commonly diagnosed cancer and the leading cause of cancer-related deaths, posing a serious health risk. Despite new advances in immune checkpoint and targeted therapies in recent years, the prognosis for lung cancer patients, especially those in advanced stages, remains poor. MicroRNAs (miRNAs) have been shown to modulate tumor development at multiple levels, and as such, miRNA mimics and molecules aimed at regulating miRNAs have shown promise in preclinical development. More importantly, miRNA-based therapies can also complement conventional chemoradiotherapy, immunotherapy, and targeted therapies to reverse drug resistance and increase the sensitivity of lung cancer cells. Furthermore, small interfering RNA (siRNA) and miRNA-based therapies have entered clinical trials and have shown favorable development prospects. Therefore, in this paper, we review recent advances in miRNA-based therapies in lung cancer treatment as well as adjuvant therapy and present the current state of clinical lung cancer treatment. We also discuss the challenges facing miRNA-based therapies in the clinical application of lung cancer treatment to provide new ideas for the development of novel lung cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Special Key Laboratory of Gene Detection and Therapy of Guizhou Province, Zunyi Medical University, Zunyi 563000, China.
- Department of Immunology, Zunyi Medical University, Zunyi 563000, China.
- Institute of Biomedical Research, Soochow University, Soochow 563000, China.
- Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine of Zunyi Medical University, Zunyi 563000, China.
Förderung
- National Natural Science Foundation of China
- Project of the Guizhou Provincial Department of Science and Technology
- Collaborative Innovation Center of the Chinese Ministry of Education
- Project of the Department of Science and Technology of Zunyi
- Graduate Research Fund of Zunyi Medical University
Zitieren
APA
Yang, H., Liu, Y., Chen, L., Zhao, J., Guo, M., Zhao, X., Wen, Z., He, Z., Chen, C., & Xu, L. (2023). MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?. Biomolecules, 13(6), 877. https://doi.org/10.3390/biom13060877
Vancouver
Yang H, Liu Y, Chen L, Zhao J, Guo M, Zhao X, et al. MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?. Biomolecules. 2023;13(6):877. doi:10.3390/biom13060877
BibTeX
@article{Yang2023,
author = {Yang, Han and Liu, Yufang and Chen, Longqing and Zhao, Juanjuan and Guo, Mengmeng and Zhao, Xu and Wen, Zhenke and He, Zhixu and Chen, Chao and Xu, Lin},
title = {MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {6},
pages = {877},
doi = {10.3390/biom13060877}
}
EUVIMED